International Journal of Risk & Safety in Medicine - Volume 3, issue 2

Article Type: Other

DOI: 10.3233/JRS-1992-3201

Citation: International Journal of Risk and Safety in Medicine, vol. 3, no. 2, pp. 61-63, 1992

Authors: Barington, Peter

Article Type: Other

DOI: 10.3233/JRS-1992-3202

Citation: International Journal of Risk and Safety in Medicine, vol. 3, no. 2, pp. 65-72, 1992

Authors: Kapp, Marshall B.

Article Type: Research Article

Keywords: U.S.A., Ethics, Drug companies, Law

DOI: 10.3233/JRS-1992-3203

Citation: International Journal of Risk and Safety in Medicine, vol. 3, no. 2, pp. 73-79, 1992

Authors: Fenger, Niels | Broberg, Morten

Article Type: Research Article

Abstract: In 1991, Denmark established a Patient Insurance Scheme, the fourth Nordic country to do so. Under the various national Nordic schemes, patients can receive indemnification for the consequences of medical injury even where the injury is not caused by negligent treatment. Instead emphasis is laid on whether the injury, viewed in retrospect, could have been avoided or whether the injury, though unavoidable, clearly exceeds the risk that the patient must accept. Differences in the four national approaches are analyzed and it is concluded that a no-fault scheme presents an elegant alternative to the tort law system, which proves to be …particularly unsatisfactory in the field of medical accidents. Show more

Keywords: Patient Insurance Act, Medical injury, Denmark, Scandinavia

DOI: 10.3233/JRS-1992-3204

Citation: International Journal of Risk and Safety in Medicine, vol. 3, no. 2, pp. 81-98, 1992

Authors: de Jong-van den Berg, L.T.W. | Cornel, M.C. | van den Berg, P.B. | Bortolussi, A.C.A. | Twerda, H.M. | Lappöhn, R.E. | Wesseling, H.

Article Type: Research Article

Abstract: This study describes the use of the ovulation stimulating drugs clomifene, human chorionic gonadotropin (hCG) and human menopausal gonadotropin (hMG) in a representative sample of a population of Dutch women in the child-bearing age group. Clomifene or hMG/hCG are seldom used alone. A considerable percentage of the women received at least four different ovulation-inducing and related drugs during the observation period of two years. Thirty percent of the women who used clomifene were treated for 6 or more cycles. These findings argue for a relative “overuse” and “misuse” of clomifene. Buserelin, a drug not registered for the indication ovulation induction …in The Netherlands but used in in vitro fertilization (IVF) programs as inhibitors of pituitary gonadotropin production, was nevertheless prescribed to 38% of the hMG /hCG users and to 11 % of the clomifene users. Our study indicates that, though the potential risks of congenital malformations due to clomifene are difficult to assess, they may be considerable; this, and the fact that different ovulation-inducing drugs are used together with clomifene, emphasizes the need for post-marketing surveillance. Show more

Keywords: Clomifene, Human chorionic gonadotropin (hCG), Human menopausal gonadotropin (hMG), Drug utilization, Pharmacy records

DOI: 10.3233/JRS-1992-3205

Citation: International Journal of Risk and Safety in Medicine, vol. 3, no. 2, pp. 99-111, 1992

Article Type: Other

DOI: 10.3233/JRS-1992-3206

Citation: International Journal of Risk and Safety in Medicine, vol. 3, no. 2, pp. 113-114, 1992

Article Type: Other

DOI: 10.3233/JRS-1992-3207

Citation: International Journal of Risk and Safety in Medicine, vol. 3, no. 2, pp. 114-114, 1992

Article Type: Book Review

DOI: 10.3233/JRS-1992-3208

Citation: International Journal of Risk and Safety in Medicine, vol. 3, no. 2, pp. 115-115, 1992

Article Type: Other

DOI: 10.3233/JRS-1992-3209

Citation: International Journal of Risk and Safety in Medicine, vol. 3, no. 2, pp. 117-118, 1992